The Hummingbird. Unitaid News – August 2019 (en anglais seulement)

Unitaid News

Aider les patients à accéder au traitement contre la tuberculose et à le suivre jusqu’au bout

Tests de haute technologie pour la tuberculose pharmacorésistante

Unitaid investit dans des technologies innovantes dans le domaine des traitements de la tuberculose

Geneva – The KNCV Tuberculosis Foundation and Unitaid signed a US$ 13.9 million grant agreement on Tuesday to increase the use of smart pillboxes and mobile technology, aiming to help patients adhere to their medicines and raise the world’s plateauing cure rates for TB.

“This project takes a familiar device, the mobile phone, and turns it into an innovative disease-fighting tool,” Unitaid Executive Director Lelio Marmora said. “So many more people will be able to adhere to the long treatment and return to good health with the support of this technology.”

The ASCENT project, starting this month and running through 2022, will pilot three types of devices and create a global market and implementation plan for them. The devices are:

  • pillboxes that send a message to a monitoring clinic every time the patient opens it up to take their medicine.
  • a video application that helps patients film themselves taking their medicine, and then sends the video to the clinic.
  • an application that helps patients send an SMS to the clinic every time they take their dose.

The project will be implemented in five countries: Ethiopia, Philippines, South Africa, Tanzania and Ukraine. KNCV will work with partners The Aurum Institute, London School of Hygiene & Tropical Medicine and PATH.

One of the difficulties in curing tuberculosis is the long treatment. Patients have to take medicines anywhere from six months to two years. After a few months of treatment, many patients feel better and stop taking their medicine. As a result, the illness returns, and the bacteria gets an opportunity to develop resistance to the tuberculosis drugs.

“KNCV Tuberculosis Foundation is excited and honored to lead the Unitaid-funded ASCENT project,” said Kitty van Weezenbeek, executive director of KNCV. “We look forward to working with national TB programs, patient representatives and our consortium partners to bring digital adherence technology to scale.”

Unitaid is investing in a host of new TB interventions, including:

  • new drug formulations for children who have multidrug-resistant TB
  • diagnosis through gene sequencing, a new technology that can analyze the genes of a patient’s particular tuberculosis bacteria and determine which drugs will work the best against it.

For more information:

Rwanda and Unitaid to collaborate on health innovations including screen-and-treat tools to prevent cervical cancer

Kigali – The Ministry of Health of Rwanda, Unitaid and Clinton Health Access Initiative (CHAI) launched a project aimed at preventing cervical cancer in Rwanda at an event led by the Minister of Health Dr. Diane Gashumba.

“Rwanda is a leading early adopter of innovation. Unitaid is delighted to bring affordable and innovative solutions to prevent cervical cancer cases in Rwanda, empowering girls and women to lead healthy lives,” Unitaid Executive Director Lelio Marmora said.

Unitaid recently signed a $33 million grant with CHAI to develop screen-and-treat solutions for preventing cervical cancer in low-resource settings for less than $1. Rwanda is among the first countries where these innovations are being implemented; the project complements Rwanda’s human papillomavirus vaccination efforts that have reached 93% of girls aged 12 years old.

“Cervical cancer can be prevented if caught early. The Government of Rwanda is pleased to join forces with Unitaid in bringing affordable screen-and-treat innovations to girls and women in Rwanda,” Dr. Gashumba said.

Unitaid and Rwanda’s Ministry of Health further signed an agreement to collaborate on better and more affordable health solutions for the people of Rwanda and beyond. The memorandum of understanding positioned Rwanda as a “champion of innovation acceleration in health” and provides a framework for the country to continue to increase access to affordable and effective health innovations that tackle the most pressing public health problems.

The visit to Rwanda also included a meeting with H.E. Mrs. Jeannette Kagame, First Lady of Rwanda and Chairperson of the Imbuto Foundation, where fruitful discussions were held about future collaboration.

Unitaid grants are directly supporting Rwanda’s health landscape through projects inside the country, and indirectly, through many other investments that develop health innovations and create the conditions for them to be widely introduced.

Examples:

  • Unitaid’s project with Innovative Vector Control Consortium is new-generation bed nets and insecticides to Rwanda’s fight against malaria. In 2018 alone, more than 800,000 Rwandans were protected with the new insecticides, including nearly 12,000 pregnant women and 118,000 children under five. Introduced at full scale, the new insecticides could avert more than 2 million cases of malaria in Rwanda between 2020 and 2024.
  • Unitaid’s project with Elizabeth Glaser Pediatric AIDS Foundation was the first to introduce integrated point-of-care early infant HIV diagnosis into national laboratory networks in Rwanda. The project allowed thousands of HIV-exposed infants to be tested, initiating lifesaving treatment within two days for 98 percent of those who tested positive.
  • Unitaid accelerated access to paediatric TB medicines by helping countries update their treatment policies, promoting demand, and creating incentives for drug companies to develop new products. In 2018, Rwanda began procuring the child-friendly formulations, which are now available in all 30 districts.
  • Unitaid’s investment in the Self Testing for Africa (STAR) project helped shape the first WHO guidelines on HIV self-testing in 2016. Rwanda now includes self-testing in its national guidelines.

For more examples please refer to the following URL: Rwanda impact note

For more information: Priyamvada CHUGH, chughp@unitaid.who.int

Rapport annuel : Unitaid à l’avant-garde de l’innovation en santé mondiale

Genève – Unitaid a le plaisir de présenter son nouveau rapport annuel. Le rapport témoigne du renforcement du rôle d’Unitaid et de la diversification de ses activités, et met en lumière sa capacité à affiner et incuber les meilleures idées en matière de santé mondiale qui seront déployées au bénéfice de millions de personnes par ses partenaires.

Le portefeuille d’Unitaid a atteint 1,3 milliard de dollars en 2019, soit plus du double qu’en 2014. Le nombre de subventions est passé quant à lui de 28 en 2014 à 48 aujourd’hui.

« Chaque jalon durement franchi montre que nous pouvons transformer des vies en un temps record en mettant en commun l’expertise des partenaires appropriés”, a déclaré Lelio Marmora, Directeur exécutif d’Unitaid. « Nous développons nos activités dans de nouveaux domaines très prometteurs et allons continuer à travailler avec les gouvernements, l’industrie, les organisations internationales et la société civile pour apporter une réponse plus cohérente et plus stratégique aux problèmes de santé mondiale. »

Le nombre d’organisations bénéficiaires d’Unitaid ne cesse d’augmenter, avec de plus en plus de partenaires originaires des pays à revenu faible et intermédiaire.

Unitaid cultive également de nouveaux types de partenariats, qui apportent des perspectives et des moyens d’action innovants. Par exemple, le partenariat entre Unitaid et MTV Staying Alive Foundation sensibilise le grand public aux autotests de dépistage du VIH à travers les épisodes de la série de télévision culte MTV Shuga.

Le travail d’Unitaid s’inscrit aujourd’hui dans la continuité des investissements et des efforts des années passées, que ce soit en termes de prévention, diagnostic ou traitement du VIH et de ses co-infections, de la tuberculose et du paludisme.

De nouveaux projets voient le jour, tels que l’amélioration du dépistage et du traitement des lésions précancéreuses du col de l’utérus, le cancer du col de l’utérus étant une cause majeure de mortalité chez les femmes vivant avec le VIH ; ou encore des méthodes innovantes de contrôle des populations de moustiques pour combattre le paludisme.

Unitaid s’est également récemment engagé dans de nouvelles approches pour faire diminuer l’inacceptable mortalité (un million de personnes par an) liée aux maladies qui atteignent particulièrement les personnes vivant avec le VIH à un stade avancé.

Enfin, plusieurs projets soutenus par Unitaid s’attaquent aux superbactéries, ces microbes résistants aux médicaments, ainsi qu’aux moustiques porteurs du paludisme et qui ne sont plus sensibles aux insecticides utilisés jusqu’à présent.

Dans un nouveau style coloré et interactif, ce rapport annuel présente les résultats et faits marquants en 2018-2019, et entraîne le lecteur dans un court mais intense voyage au cœur des activités d’Unitaid.

The Hummingbird. Unitaid News – June 2019 (en anglais seulement)

Unitaid News_June 2019

L‘investissement de l‘Unitaid dans la lutte contre la tuberculose enregistre un niveau record grâce à un nouveau financement en faveur des technologies de diagnostic

Geneva – The Foundation for Innovative New Diagnostics (FIND) and Unitaid signed a US$ 14.5 million grant Thursday to deploy a powerful new technology in the diagnosis of drug-resistant tuberculosis.

The Seq&Treat project will pilot next-generation genome sequencing, an innovation that provides fast, accurate diagnosis of drug-resistant TB. Better diagnosis enables patients to get the right treatment earlier, and could help raise the world’s very low cure rate for the disease.

The technology also has the potential to be an effective weapon in the fight against drug-resistant superbugs, which develop when medicines are misused.

The new investment is part of a dramatic expansion in Unitaid’s TB portfolio, which has nearly doubled over the past few years and is on track to hit US$ 300 million in 2020.

“New technologies offer a phenomenal pathway to test and treat more people for tuberculosis, including drug-resistant TB, while strengthening health systems,” said Lelio Marmora, Unitaid’s executive director.

The three-year Seq&Treat project will be implemented in Brazil, China, Georgia, India and South Africa. FIND will work closely with civil society organizations in those countries to make communities familiar with the project and its aims, and to facilitate transition and scale-up. FIND will also leverage relationships with global civil society organizations to advocate for improved access to diagnostics.

In 2017, only a quarter of the estimated 558,000 people with drug-resistant TB started treatment, and less than 14 percent were cured.

Sequencing-based tests can produce results in 48 hours, a vast improvement over  culture-based tests that require up to eight weeks. The technology could also yield large savings in treatment costs, because it enables clinicians to prescribe the right medicine to patients from the outset of their treatment.

Sequencing devices also support integrated approaches to health care; they can be used to diagnose multiple diseases at the same time, which can lead to a cure for more patients.

“Integrated approaches are a strategic priority for Unitaid and support the UN Sustainable Development Goals. With this type of project we are seeking to invest in products that impact health systems,” Unitaid Board Chair Marisol Touraine said.

Unitaid’s is the largest multilateral investor in TB research and development, a reflection of the organization’s commitment to confront the world’s leading infectious killer.

For more information: Carol MASCIOLA, masciolac@unitaid.who.int